Dynavax to get $6 million payment from Glaxo for new lupus drug
Biotechnology company Dynavax Technologies Corp. said Wednesday it will receive a $6 million milestone payment from partner GlaxoSmithKline after it started a study on a potential lupus drug.
Dynavax started early-stage testing on DV1179. The Phase 1 clinical trial is aimed at testing safety and will involve 24 healthy subjects.
Dynavax and GlaxoSmithKline have been partners since 2008 on inhibitors of endosomal toll-like receptors, or TLRs, for the treatment of immuno-inflammatory diseases. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.